News

Stories

See all

Testing for the Novel Coronavirus

View Story

Lilly Accelerates Cancer R&D with Speed and Precision

View Story

Genomic Testing in Cancer

View Story

Cancer Care Beyond Medicine

View Story

Updates: Lilly's Global COVID-19 Response

View Story

three Lilly scientists talking in a lab

DiversityInc No. 3 Ranking Highlights Our Inclusive Culture

View Story


  1. 1

Press Releases

See all

Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

May 29, 2020

Tags |  Product

CYRAMZA, in combination with erlotinib, now approved for the treatment of people with untreated metastatic non-small cell lung cancer (NSCLC) with certain activating EGFR mutations, based on the positive global Phase 3 RELAY study   CYRAMZA regimen reduced the risk of disease progression or death




Lilly Receives U.S. FDA Approval of TAUVID™ (flortaucipir F 18 injection) for Use in Patients Being Evaluated for Alzheimer's Disease

May 28, 2020

Tags |  Product

The first and only approved diagnostic agent to image tau neurofibrillary tangles in the brain INDIANAPOLIS , May 28, 2020 /PRNewswire/ -- TAUVID ™ , a radioactive diagnostic agent, has been approved by the FDA for positron emission tomography (PET) imaging of the brain to estimate the density and




Statement from Lilly Chairman and CEO Dave Ricks on New Part D Senior Savings Model

May 26, 2020

Tags |  Product

INDIANAPOLIS , May 26, 2020 /PRNewswire/ -- President Donald J. Trump and Seema Verma , Administrator for the Centers for Medicare & Medicaid Services , today announced details of the new Part D Senior Savings Model that will allow people in the Medicare Part D program to buy their monthly




Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance's® effects following an acute myocardial infarction

May 26, 2020

Tags |  Product

- Ischemic heart disease, including myocardial infarction, is the leading cause of death in the U.S. - EMPACT-MI is the first trial in the SGLT2 inhibitor class to investigate the prevention of heart failure after acute myocardial infarction in adults with and without diabetes - The trial is part